KR860008176A - 8-페닐크산틴류의 제조방법 - Google Patents

8-페닐크산틴류의 제조방법 Download PDF

Info

Publication number
KR860008176A
KR860008176A KR1019860003211A KR860003211A KR860008176A KR 860008176 A KR860008176 A KR 860008176A KR 1019860003211 A KR1019860003211 A KR 1019860003211A KR 860003211 A KR860003211 A KR 860003211A KR 860008176 A KR860008176 A KR 860008176A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
alkyl
formula
nitro
Prior art date
Application number
KR1019860003211A
Other languages
English (en)
Inventor
메리 달루지 수잔
제퍼슨 라이톤 해리
Original Assignee
마이클 피터 잭슨
더 웰컴 파운데이숀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이클 피터 잭슨, 더 웰컴 파운데이숀 리미티드 filed Critical 마이클 피터 잭슨
Publication of KR860008176A publication Critical patent/KR860008176A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Abstract

내용 없음

Description

8-페닐크산틴류의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 상화 방지제의 존재하에서, 하기식(Ⅱ)의 화합물을 고리화하거나, 하기 기중 Y가 C3-6알케닐렌옥시 또는 C3-6알키닐렌옥신인 경우 하기식(Ⅶ)의 화합물을 하기식(Ⅷ)의 화합물과 반응시키거나, 하기식(Ⅹ)의 화합물을 고리화하고, 그 후 결과의 하기식(Ⅰ)의 화합물의 기중 X1내지 X6를 각각 상이한 X1내지 X6로 전환시키거나 하기식(Ⅰ)의 화합물의 염 또는 그 용매 화합물을 형성하는 단계로 구성되는 하기식(Ⅰ)의 화합물, 이것의 염 또는 이것의 용매 화합제조하는 방법.
    상기식에서, X1및 X3는 서로 상이하거나 동일한 수소, C1-6알킬, C2-6알케닐 또는 아릴링에 C1-6알킬, C1-6알콕시, 히드록시, 할로, 니트로, 아미노 아지도, 및 시아노로부터 선택된 적어도 하나의 치환제에 의해 치환된 C7-12아르알킬로서, X1및 X2가 모두 수소가 아님을 조건으로 하여 ; X3및 X4중 어느하나는 수소, C1-6알킬, 트리플루오로메틸, C1-6알콕시, 할로, 니트로, 아미노,C1-6알콕시카르보닐 또는 카르복시이며, 다른 하나는 -Y-Z인데, Y는 C2-6알케닐렌, C3-6알케닐 렌옥시, C2-6알키닐렌 또는 C3-6알킬닐렌옥시이며, Z는 카르복시, 설포닐 또는 포스포닐 또는 C1-9알킬에스테르, C7-12아르알킬에스테르 또는 C6-12아릴에스테르이거나 혹은 5-테트라졸릴이며 ; X5및 X6는 서로 상이하거나 동일한 산소 또는 황이며 ; X1 3및 X1 4중 어느하나는 상기의 X3및 X4중 어느하나로서 정의괸 바와 같으며, 다른 하나는 히드록시이며 ; L은 이탈기이며 ; Y1은 C3-6알케닐렌 또는 C3-6알키닐렌이며 ; A 및 B중 어느 하나는 수소이며, 다른 하나는 3-X3)-4-(X4)-벤조일(X3및 X4는 상기에서 정의된 바와 같음)이다.
  2. 제1항에 있어서, X1및 X2중 어느하나 혹은 모두는 아릴에 C1-6알킬, C1-6알콕시, 히드록시, 할로, 니트로, 아미노, 아지도 및 시아노보쿠터 선택된 적어도 하나의 치환체에 의해 임의적으로 치환된 벤질인 것을 특징으로 하는 제조방법.
  3. 제2항에서, 상기 임의의 치환체는 메틸, 메톡시, 히드록시, 클로로, 니트로, 아미노, 아지도 및 시아노로부터 선택되는 것을 특징으로 하는 제조방법.
  4. 제1항 내지 제3항중 어느 한항에 있어서, X1및 X2는 수소 또는 C1-6알킬인 것을 특징으로 하는 제조방법.
  5. 제1항 내지 제4항중 어느 한항에 있어서, Y는 비닐렌 또는 아세틸렌인 것을 특징으로 하는 제조방법.
  6. 제1항 내지 제5항중 어느 한항에 있어서, X3는 수소이며, X4는 -Y-Z인데, Y는 비닐렌이고 Z는 카르복시 또는 이것의 C1-6에스테르인 것을 특징으로 하는 제조방법.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860003211A 1985-04-27 1986-04-25 8-페닐크산틴류의 제조방법 KR860008176A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858510758A GB8510758D0 (en) 1985-04-27 1985-04-27 Compounds
GB8510758 1985-04-27

Publications (1)

Publication Number Publication Date
KR860008176A true KR860008176A (ko) 1986-11-12

Family

ID=10578311

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860003211A KR860008176A (ko) 1985-04-27 1986-04-25 8-페닐크산틴류의 제조방법

Country Status (22)

Country Link
US (2) US4879296A (ko)
EP (1) EP0203721B1 (ko)
JP (1) JPH0788381B2 (ko)
KR (1) KR860008176A (ko)
AP (1) AP22A (ko)
AT (1) ATE77088T1 (ko)
AU (1) AU581507B2 (ko)
CA (1) CA1286666C (ko)
DE (1) DE3685608T2 (ko)
DK (1) DK169271B1 (ko)
ES (1) ES8800945A1 (ko)
FI (1) FI861750A (ko)
GB (1) GB8510758D0 (ko)
GR (1) GR861107B (ko)
HU (1) HUT41027A (ko)
IE (1) IE60022B1 (ko)
IL (1) IL78605A (ko)
MC (1) MC1743A1 (ko)
NO (1) NO861643L (ko)
NZ (1) NZ215948A (ko)
PT (1) PT82451B (ko)
ZA (1) ZA863132B (ko)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710503A (en) * 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
AT388500B (de) * 1987-10-27 1989-06-26 Wellcome Found Antivirale 8-phenylxanthine
US5310916A (en) * 1988-07-19 1994-05-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
WO1990012797A1 (en) * 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sulfer-containing xanthine derivatives as adenosin antagonists
WO1991016056A1 (en) * 1990-04-16 1991-10-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Use of purinergic receptor agonists as antineoplastic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0541120B1 (en) * 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
US5300298A (en) * 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
TW252044B (ko) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
US6025361A (en) 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
EP0814809B1 (en) 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
DE69531555T2 (de) * 1994-12-13 2004-06-17 Euroceltique S.A. Dreifachsubstituierte thioxanthine
US5733932A (en) * 1995-01-06 1998-03-31 The Picower Institute For Medical Research Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6316423B1 (en) 1996-04-10 2001-11-13 The United States Of America As Represented By The Departmant Of Health And Human Services Method of treating ischemic, hypoxic and anoxic brain damage
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6063363A (en) * 1997-05-27 2000-05-16 Goodwin; Gary J Treatment for upper respiratory tract infections with potassium salts
AU1722999A (en) 1997-12-12 1999-07-05 Euro-Celtique S.A. Preparation of 3-substituted adenines and imidazo pyridines
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6319928B1 (en) 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
AU4053800A (en) 1999-04-02 2000-10-23 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US7253176B1 (en) * 2000-05-04 2007-08-07 K.U. Leuven Research & Development Immunosuppressive effects of 8-substituted xanthine derivatives
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
JP4514452B2 (ja) * 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
UA84404C2 (ru) * 2002-06-12 2008-10-27 Байоджен Айдек Ма Инк. Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина
JP2006518390A (ja) * 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
DE60322748D1 (de) * 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
CN101068825B (zh) * 2004-08-02 2013-05-08 弗吉尼亚大学专利基金会 具有a2a激动剂活性的具有修饰的5＇-核糖基团的2-丙炔基腺苷类似物
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
RU2385322C2 (ru) * 2004-09-01 2010-03-27 Си Ви Терапьютикс, Инк. Способ заживления ран с применением антагонистов аденозинового рецептора a2b
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en) 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2602795A (en) * 1950-06-24 1952-07-08 Searle & Co Hydroxyalkyl alkyl derivatives of 5-nitroso-6-amino-1, 2, 3, 4-tetrahydro-2, 4-pyrimidinedione
US4452788A (en) 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
US4612315A (en) * 1984-10-26 1986-09-16 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3522230A1 (de) * 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
ES8800945A1 (es) 1987-12-01
EP0203721B1 (en) 1992-06-10
ES554380A0 (es) 1987-12-01
AP8600036A0 (en) 1986-02-01
IE60022B1 (en) 1994-05-18
AP22A (en) 1988-07-20
EP0203721A2 (en) 1986-12-03
IL78605A (en) 1989-07-31
US4981857A (en) 1991-01-01
HUT41027A (en) 1987-03-30
JPS6242986A (ja) 1987-02-24
PT82451A (en) 1986-05-01
CA1286666C (en) 1991-07-23
EP0203721A3 (en) 1988-06-08
DK190486A (da) 1986-10-28
MC1743A1 (fr) 1987-02-26
DK190486D0 (da) 1986-04-24
ZA863132B (en) 1987-12-30
NZ215948A (en) 1989-10-27
NO861643L (no) 1986-10-28
AU5670786A (en) 1986-10-30
DK169271B1 (da) 1994-09-26
PT82451B (pt) 1988-11-30
IE861104L (en) 1986-10-27
FI861750A (fi) 1986-10-28
AU581507B2 (en) 1989-02-23
DE3685608D1 (de) 1992-07-16
FI861750A0 (fi) 1986-04-25
IL78605A0 (en) 1986-08-31
GB8510758D0 (en) 1985-06-05
GR861107B (en) 1986-08-04
US4879296A (en) 1989-11-07
ATE77088T1 (de) 1992-06-15
DE3685608T2 (de) 1992-12-24
JPH0788381B2 (ja) 1995-09-27

Similar Documents

Publication Publication Date Title
KR860008176A (ko) 8-페닐크산틴류의 제조방법
KR850003890A (ko) 1H-이미다조[4,5c]-퀴놀린-4-아민의 제조방법
AU600897B2 (en) N-acyl-alpha-amino-alpha-hydroxy acetic acid ester
KR830007662A (ko) 5,6,7,7a-테트라하이드로-4H-티에노 [3,2-c]-피리딘-2-온 유도체의 제조방법
KR840006482A (ko) 디히드로피라졸로 [3,4-b]피리딘 유도체의 제조방법
DE3578178D1 (de) Beta-carbolin-3-carbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung.
BR8606955A (pt) Processo para preparar uma composicao,concentrado aditivo,composicao lubrificante,composicao combustivel e metodo para reduzir o consumo de combustivel
AU8136291A (en) 4-amino-delta4-steroids and their use as 5alpha-reductase inhibitors
KR840008323A (ko) 5-아실-2-(1h)-피리디논의 제조방법
KR830007655A (ko) 벤조디아제핀 화합물의 제조 방법
KR850002988A (ko) 페니실린 유도체의 제조방법
KR830006302A (ko) 신규 피리미딘 유도체의 제조방법
ATE241976T1 (de) N,n'-bis (sulfonyl) hydrazine die als antineoplastische mittel nützlich sind
KR840000530A (ko) 신규 벤조트리아졸의 제조방법
KR960004326A (ko) 3-치환된 퀴놀린-5- 카르복실산 유도체 및 그의 제조 방법
KR890002193A (ko) 우선성의 3-(3-피리딜)-1H,3H- 피롤로[1,2-c]-7-티아졸카르복실산의 제조방법
KR870004038A (ko) 제초제 화합물의 제조방법
KR920006306A (ko) 4-메틸술포닐 벤조산유도체의 제조방법 및 그 중간체화합물
ATE14125T1 (de) 5-(4-phenyl-1-piperidinyl)methyl-2,3-dihydro-2oxo-1h-imidazol-4-carbonsaeure-derivate.
GB1481032A (en) Glutamyl amide derivatives of dopamine
KR880012555A (ko) 피리딘-2,3-디카르복실산 또는 그의 유도체를 제조하는 방법과 그 방법에 의해 제조된 화합물
KR850004758A (ko) 피라졸로 피리딘 유도체의 제법
KR850006406A (ko) 4,7-디히드로피라졸[3,4-b] 피리딘 유도체의 제조방법
KR910000619A (ko) γ-케토-δ-아미노산 유도체의 거울이성체 선택 제조방법
GB1482069A (en) Imidazolones as stabilisers for organic material

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E601 Decision to refuse application